GTH
- Genetron Holdings Limited
()
Overview
Company Summary
Genetron Holdings Limited (GTH) is a leading precision oncology company that specializes in developing and commercializing molecular profiling tests, known as companion diagnostics, for cancer diagnosis and treatment. The company aims to transform cancer care through advanced genomics and diagnostic technologies.
Genetron operates through two business segments:
1. Molecular Profiling Services: Genetron provides advanced molecular profiling services to healthcare providers, pharmaceutical companies, and research organizations. Using cutting-edge genetic sequencing technologies and bioinformatics analysis, the company identifies genetic alterations and abnormalities in tumor cells. This information helps to guide personalized treatment plans, monitor treatment response, and identify potential drug targets.
2. Companion Diagnostics: Genetron develops and commercializes companion diagnostic tests that are specifically designed to identify genetic alterations in cancer cells. These tests are intended to help physicians select the most appropriate targeted therapies for their patients. By analyzing the genetic makeup of tumors, these tests can improve treatment outcomes and reduce the risk of adverse reactions to specific therapies.
Additionally, Genetron collaborates with pharmaceutical companies and clinical research organizations to develop and validate new companion diagnostics. By partnering with these organizations, Genetron aims to advance precision medicine and contribute to the development of novel targeted therapies.
Overall, Genetron Holdings Limited plays a crucial role in precision oncology by providing molecular profiling services and developing companion diagnostics that enable healthcare professionals to make informed decisions for cancer diagnosis and treatment.